scPharmaceuticals Inc. (SCPH)
5.67
0.00 (0.00%)
Inactive · Last trade price
on Oct 6, 2025
scPharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for scPharmaceuticals stock had an average target of 12, with a low estimate of 6.00 and a high estimate of 18.
Price Target: $12.00 (+111.64%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 26, 2025.
Analyst Ratings
The average analyst rating for scPharmaceuticals stock from 3 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy → Hold Downgrades $6 | Strong Buy → Hold | Downgrades | $6 | +5.82% | Aug 26, 2025 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 25, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $20 → $12 | Strong Buy | Maintains | $20 → $12 | +111.64% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +217.46% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +217.46% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
74.23M
from 36.33M
Increased by 104.30%
Revenue Next Year
130.68M
from 74.23M
Increased by 76.06%
EPS This Year
-1.11
from -1.91
EPS Next Year
-0.16
from -1.11
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 78.8M | 157.5M | |||
| Avg | 74.2M | 130.7M | |||
| Low | 69.6M | 117.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 116.8% | 112.2% | |||
| Avg | 104.3% | 76.1% | |||
| Low | 91.5% | 57.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.10 | 0.21 | |||
| Avg | -1.11 | -0.16 | |||
| Low | -1.10 | -0.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.